Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References References Top-line results for CANOPY-1 1 2 3 4 5 Novartis Data on File ClinicalTrials.gov. Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A (Canopy-A). Available at: https://www.clinicaltrials.gov/ct2/show/NCT03447769. Accessed on September 10, 2021. Ridker PM, Thuren T, Zalewski A, et al. Interleukin-1ẞ inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011;162:597-605. ClinicalTrials.gov. Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects (CANOPY-1). Available at: https://clinicaltrials.gov/ct2/show/NCT03631199. Accessed on September 10, 2021. ClinicalTrials.gov. Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers. Available at: https://clinicaltrials.gov/ct2/show/NCT03798626. Accessed September 10, 2021 6 Jayaraman. P. Targeting IL-1ẞ pathway for cancer immunotherapy. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30 CosentyxⓇ peak sales expectations 1 2 Market defined as US + EU5 Biologics in PsO, PsA and AS. Source: US: IQVIA PADDS Monthly Jul'21 and Indication split% from SHS PTD for disease% for 2018 used for PSA, AS and IQVIA Medical for PSO. EU5- IQVIA Monthly Jul'21, CPO Inputs Jun'21 and IQVIA Padds Jul'21 PSO: DRG + IQVIA patient equivalents. SpA: Aligned with DRG and multiple internal sources EntrestoⓇgrew +44% in the quarter 1 2021 Update to the 2017 ACC Expert Consensus Decision Pathway (ECDP) for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. https://www.jacc.org/doi/10.1016/j.jacc.2020.11.022 2 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure https://doi.org/10.1093/eurhearti/ehab368 3 IQVIA National Prescription Audit as of 24/09/2021 EntrestoⓇ peak sales expectations 1 Eligible patients defined as prevalent HFrEF patients within each market's label. G7 = US, CA, JP, DE, FR, IT, UK 2 Including but not limited to CA, SP, UK LeqvioⓇ on track for US launch 1 In patients with elevated LDL-C despite treatment with maximally tolerated statin therapy. V-INITIATE NCT04929249; V-INCEPTION NCT04873934 137 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation